A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors
- Michael S. Gordon*
- , Lee S. Rosen
- , David Mendelson
- , Ramesh K. Ramanathan
- , Jonathan Goldman
- , Lili Liu
- , Yan Xu
- , Stanton L. Gerson
- , Stephen P. Anthony
- , William D. Figg
- , Shawn Spencer
- , Bonne J. Adams
- , Charles P. Theuer
- , Bryan R. Leigh
- , Glen J. Weiss
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
34
Scopus
citations